Combination of Zanubrutinib, Rituximab and Venetoclax in Patients With Previously Untreated Follicular Lymphoma

Exclusion Criteria

• •ECOG≤ 2
• •Absolute neutrophil count (ANC) \> 1.0 x 10\^9/L
• •Platelet count \> 50 x 10\^9/L
• •Prothrombin time (PT)/international normal ratio (INR) \< 1.5 x (upper limit of normal) ULN and partial thromboplastin time (PTT) (activated partial thromboplastin time \[aPTT\]) \< 1.5 x ULN (unless abnormalities are unrelated to coagulopathy or bleeding disorder). When treated with warfarin or other vitamin K antagonists, then INR ≤ 3.0)
• •Serum aspartate transaminase (AST) and alanine transaminase (ALT) \< 3 x upper limit of normal (ULN)
• •Creatinine clearance \> 30 ml/min calculated by modified Cockcroft-Gault formula
• •Bilirubin \< 1.5 x ULN unless bilirubin is due to Gilbert's syndrome, documented liver involvement with lymphoma, or of non-hepatic origin, in which case bilirubin should not exceed 3 g/dL
• •Women of childbearing potential must have a negative serum (beta-human chorionic gonadotropin \[B-hCG\]) pregnancy test at screening. Women who are pregnant or breastfeeding are ineligible for this study
• •Known active central nervous system lymphoma or leptomeningeal disease
• •Follicular lymphoma with evidence of diffuse large B-cell transformation
• •Grade 3b follicular lymphoma
• •Any prior history of other malignancy besides follicular lymphoma
• •History of severe allergic or anaphylactic reactions to monoclonal antibody therapy
• •Patients who have undergone major surgery within 14 days
• •The researchers believe that it is not advisable for the participant to take part in this trial.